Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660
01/09/2026 11:10
BRIEF-Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660 Sept 1 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK:
ENTERS EXCLUSIVE GLOBAL LICENSING AGREEMENT WITH ROCHE FOR SIM0660 ON SEPT 1, 2026
ELIGIBLE FOR TIERED ROYALTIES OF UP TO DOUBLE DIGITS ON FUTURE NET SALES
ELIGIBLE FOR $75 MILLION UPFRONT AND UP TO $1.46 BILLION IN MILESTONE PAYMENTS
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey